Kanerkinden, Switzerland

Alain Mesmaeker

This inventor holds 1 USPTO granted patent. Top assignee: Ciba-Geigy Corporation. Active years: 1996.


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 180(Granted Patents)


Company Filing History:


Years Active: 1996

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Alain Mesmaeker: Innovator in Nucleoside Phosphinate Compounds

Introduction

Alain Mesmaeker is a notable inventor based in Kanerkinden, Switzerland. He has made significant contributions to the field of chemistry, particularly in the development of nucleoside phosphinate compounds. His work has implications for pharmaceutical applications, showcasing the intersection of innovation and healthcare.

Latest Patents

Alain Mesmaeker holds a patent for "Nucleoside phosphinate compounds and compositions." This patent describes a compound of a specific formula where various radicals and groups are defined, including aliphatic, aromatic, and cycloaliphatic radicals. The patent also outlines a method for preparing these compounds and their potential use as pharmaceutical agents. He has 1 patent to his name.

Career Highlights

Throughout his career, Alain Mesmaeker has been associated with Ciba-Geigy Corporation, a prominent player in the pharmaceutical and chemical industries. His work at the company has allowed him to focus on innovative solutions in drug development and chemical synthesis.

Collaborations

Alain has collaborated with notable colleagues such as Anthony D. Baxter and Eric K. Baylis. These collaborations have likely contributed to the advancement of his research and the successful development of his patented compounds.

Conclusion

Alain Mesmaeker's contributions to the field of nucleoside phosphinate compounds highlight his role as an innovator in chemistry. His work not only advances scientific knowledge but also has the potential to impact pharmaceutical applications significantly.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…